Immunic appoints MS expert Dr. Richard Rudick to Board; Dr. Ossipow to retire at 2023 meeting

IMMUNIC, INC.

Dr. Rudick appointed as Class III director effective April 26, 2023; term ends at 2023 Annual Meeting.
Received option to purchase 32,000 shares, vesting monthly over three years, exercise price at grant date closing price.
Dr. Vincent Ossipow will not stand for re-election at 2023 Annual Meeting, continues until then; no disagreement cited.
Board size increased from 7 to 8 directors upon Rudick's appointment.
Rudick brings 35+ years of MS expertise from Cleveland Clinic and Biogen, expected to support vidofludimus calcium development.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Vincent Ossipow

Director

IMUX · IMMUNIC, INC.

Filed: April 27, 2023, 7:59 PM ET

Additionally, on April 26, 2023, Dr. Vincent Ossipow notified the Board that he plans to retire from the Board at the end of his current term and will not stand for re-election at the 2023 Annual Meeting.

Appointed

Dr. Richard Rudick

Director

IMUX · IMMUNIC, INC.

Effective: 2023-04-26
Filed: April 27, 2023, 7:59 PM ET

On April 27, 2023, Immunic, Inc. (the “Company”) announced the appointment of Dr. Richard Rudick as a member of the Board of Directors (the “Board”) of the Company, effective as of April 26, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Vincent Ossipow departed as Director at IMMUNIC, INC..

Action: plans to retire
Role: Director

Exact text from the filing

Additionally, on April 26, 2023, Dr. Vincent Ossipow notified the Board that he plans to retire from the Board at the end of his current term and will not stand for re-election at the 2023 Annual Meeting.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Richard Rudick was appointed as Director at IMMUNIC, INC..

Action: appointed
Role: Director

Exact text from the filing

On April 27, 2023, Immunic, Inc. (the “Company”) announced the appointment of Dr. Richard Rudick as a member of the Board of Directors (the “Board”) of the Company, effective as of April 26, 2023.

View on SEC.gov

IMMUNIC, INC. filing history →

Source: SEC EDGAR

accession 0001193805-23-000611

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.